Openbookopenbook
Equity
Rapid Nutrition PLC(0RNS)
EUR --+0.00%
Reward49Moderate
Risk41Moderate
📊50%Data
Revenue down 59% YoY
0RNS
+0.0 · +0.00%
EUR · LSE
Rapid Nutrition PLC |
Earnings Deterioration
Market Cap:—
ℹ️
Reward Rating
49
Moderate
Bottom 50% (model universe)
50% data coverage
ℹ️
Risk Rating
41
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0RNS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Rapid Nutrition PLC?

Rapid Nutrition PLC, a natural healthcare company, develops and distributes science-based health and wellness products worldwide.

0RNS · Verdict

Moderate reward · moderate risk

0RNS stands out on balance sheet and volatility, but watch the profitability signal.

Based on 75% data coverage

0RNS · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet84/100

    Current ratio 1.65

  • Volatility75/100

    Above average

Watchouts 2

  • Profitability10/100

    -183% return on equity

  • Cash flow30/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Rapid Nutrition PLC?

Rapid Nutrition PLC, a natural healthcare company, develops and distributes science-based health and wellness products worldwide. The company offers natural and organic ingredients designed for weight loss under the System LS brand; herbal medicine for symptoms of sore throat, colds, and flu, as well as added Ashwagandha and Andrographis for strong immunity boost for travelers under the Azurene brand. The company is listed on the LSE in UK, and a P/E ratio of 26.6x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (49)

The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market CapN/A
P/E Ratio26.6
Dividend YieldN/A
52 Week High15
52 Week Low2.4
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares OutstandingN/A
No. of Employees12
IndustryN/A
ExchangeLSE
Beta-0.253
CurrencyEUR
Websitewww.rnplc.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.